(BUSINESS WIRE)--Kinagen is an emerging drug discovery and development company, positioned to establish a new class of drugs that stabilize kinases in an inactive state. The drug discovery approach embodied in the Kinagen Platform™ provides efficacy and safety advantages that will result in improved treatments for patients. Kinagen’s RAF Blockade™ drug candidate addresses limitations of other approaches and promises to provide durable benefits to a broad range of cancer patients.
